Cytochalasin B (Phomin)
(Synonyms: 细胞松弛素B; Phomin) 目录号 : GC32890
Cytochalasin B(细胞松弛素B)是一种可渗透细胞的真菌毒素,从Phoma属的子囊菌真菌中分离得到[1-2]。
Cas No.:14930-96-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Human mesenchymal stem cells (hMSCs) |
|
Preparation Method |
Cells were cultured in the presence of Cytochalasin B or 0.05% DMSO. |
|
Reaction Conditions |
0.1-10 µM; 0-72 h |
|
Applications |
Cytochalasin B influenced the metabolism, proliferation, and morphology of hASCs in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Balb/c mice (bearing P388/ADR leukemias) |
|
Preparation Method |
Mice (bearing P388/ADR leukemias) were administered with Cytochalasin B on Days 1-8. |
|
Dosage form |
Cytochalasins B was prepared in suspension form in 2% carboxymethyl cellulose 1% tween 20 (CMC/Tw); i.p.;10, 25, or 50 mg/kg; 8days |
|
Applications |
Cytochalasin B dose-dependently increases the life expectancy of Balb/c mice bearing with P388/ADR leukemias. |
|
References: [1]. Bianconi E, Tassinari R, et,al. Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells. Cells. 2022 May 12;11(10):1629. doi: 10.3390/cells11101629. PMID: 35626666; PMCID: PMC9139657. |
|
Cytochalasin B is a cyto-permeable mycotoxin, and it is isolated from an ascomycete fungus belonging to the Phoma genus[1-2]. Cytochalasin B is able to inhibit the formation of actin microfilaments through a direct effect on the polymerization of the cytoskeletal protein. By binding the fast-growing end of F-actin and interacting with capping proteins, influences the nucleation-elongation of actin microfilaments[3-4].
Cytochalasin B (0.1-10 µM; 0-72 h) influenced the metabolism, proliferation, and morphology of hASCs in a dose-dependent manner, in association with progressive disorganization of actin microfilaments[5]. Cytochalasin B is capable of inducing DNA fragmentation in a number of cells lines[6]. Cytochalasin B (10-8-10-1M; 24-96 h) effectively inhibited U251 cell proliferation in a dose- and time-dependent manner. Cytochalasin B increased the proportion of cells in the G2/M phase in a dose-dependent manner, thus increasing the mitotic index and decreasing CDC2 and cyclin B1 protein levels[7].
Cytochalasin B(Cytochalasins B was prepared in suspension form in 2% carboxymethyl cellulose 1% tween 20 (CMC/Tw); i.p.;10, 25, or 50 mg/kg; 8days ) dose-dependently increases the life expectancy of Balb/c mice bearing with P388/ADR leukemias[8].Cytochalasin B(5 µg/ml Cytochalasin B; 30 min) treatment of mouse oocytes during intracytoplasmic sperm injection (ICSI) increases embryo survival without impairment of development[9].
References:
[1]. Van Goietsenoven G, Mathieu V, et,al. In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med. 2011 May;77(7):711-7. doi: 10.1055/s-0030-1250523. Epub 2010 Nov 5. PMID: 21058241.
[2]. Trendowski M. Using cytochalasins to improve current chemotherapeutic approaches. Anticancer Agents Med Chem. 2015;15(3):327-35. doi: 10.2174/1871520614666141016164335. PMID: 25322987; PMCID: PMC4485394.
[3]. MacLean-Fletcher S, Pollard TD. Mechanism of action of cytochalasin B on actin. Cell. 1980 Jun;20(2):329-41. doi: 10.1016/0092-8674(80)90619-4. PMID: 6893016.
[4]. Flanagan MD, Lin S. Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem. 1980 Feb 10;255(3):835-8. PMID: 7356663.
[5]. Bianconi E, Tassinari R, et,al. Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells. Cells. 2022 May 12;11(10):1629. doi: 10.3390/cells11101629. PMID: 35626666; PMCID: PMC9139657.
[6]. Kolber MA, Broschat KO, et,al. Cytochalasin B induces cellular DNA fragmentation. FASEB J. 1990 Sep;4(12):3021-7. doi: 10.1096/fasebj.4.12.2394319. PMID: 2394319.
[7]. Tong ZG, Liu N, et,al. Cytochalasin B inhibits the proliferation of human glioma U251 cells through cell cycle arrest and apoptosis. Genet Mol Res. 2014 Dec 19;13(4):10811-22. doi: 10.4238/2014.December.19.2. PMID: 25526201.
[8]. Trendowski M, Mitchell JM, et,al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. doi: 10.1007/s10637-014-0203-5. Epub 2015 Jan 7. PMID: 25563824; PMCID: PMC4387261.
[9].Hu LL, Shen XH, et,al. Cytochalasin B treatment of mouse oocytes during intracytoplasmic sperm injection (ICSI) increases embryo survival without impairment of development. Zygote. 2012 Nov;20(4):361-9. doi: 10.1017/S0967199411000438. Epub 2011 Aug 15. PMID: 21838963.
Cytochalasin B(细胞松弛素B)是一种可渗透细胞的真菌毒素,从Phoma属的子囊菌真菌中分离得到[1-2]。它能够通过直接影响细胞骨架蛋白的聚合来抑制肌动蛋白微丝的形成。通过结合F-肌动蛋白的快速生长端并与封盖蛋白相互作用,影响肌动蛋白微丝的成核伸长[3-4]。
Cytochalasin B (0.1-10 µM;0-72 h)以剂量依赖的方式影响hASCs细胞的代谢、增殖和形态,这与肌动蛋白微丝的逐渐解体有关[5]。Cytochalasin B能够在许多细胞系中诱导DNA断裂[6]。Cytochalasin B (10-8-10-1M;24-96 h)有效抑制U251细胞增殖。Cytochalasin B以剂量依赖的方式增加G2/M期细胞的比例,从而增加有丝分裂指数,降低CDC2和cyclin B1蛋白水平[7]。
Cytochalasin B (Cytochalasins B was prepared in suspension form in 2% carboxymethyl cellulose 1% tween 20 (CMC/Tw); i.p.;10, 25, or 50 mg/kg; 8days)剂量依赖性地增加P388/ADR白血病Balb/c小鼠的预期寿命[8]。对小鼠卵母细胞进行胞浆内精子注射(ICSI)期间的Cytochalasin B(5 µg/ml Cytochalasin B; 30 min) 处理增加了胚胎的存活率,而不影响发育[9]。
| Cas No. | 14930-96-2 | SDF | |
| 别名 | 细胞松弛素B; Phomin | ||
| Canonical SMILES | O=C1N[C@@H](CC2=CC=CC=C2)[C@@]3([H])[C@]14[C@](/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(O4)=O)([H])[C@H](O)C([C@H]3C)=C | ||
| 分子式 | C29H37NO5 | 分子量 | 479.61 |
| 溶解度 | DMSO: ≥ 100 mg/mL (208.50 mM); Ethanol: 25 mg/mL (52.13 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.085 mL | 10.4251 mL | 20.8503 mL |
| 5 mM | 0.417 mL | 2.085 mL | 4.1701 mL |
| 10 mM | 0.2085 mL | 1.0425 mL | 2.085 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells
Cells 2022 May 12;11(10):1629.PMID:35626666DOI:10.3390/cells11101629.
Cytoskeletal proteins provide architectural and signaling cues within cells. They are able to reorganize themselves in response to mechanical forces, converting the stimuli received into specific cellular responses. Thus, the cytoskeleton influences cell shape, proliferation, and even differentiation. In particular, the cytoskeleton affects the fate of mesenchymal stem cells (MSCs), which are highly attractive candidates for cell therapy approaches due to their capacity for self-renewal and multi-lineage differentiation. Cytochalasin B (CB), a cyto-permeable mycotoxin, is able to inhibit the formation of actin microfilaments, resulting in direct effects on cell biological properties. Here, we investigated for the first time the effects of different concentrations of CB (0.1-10 μM) on human adipose-derived stem cells (hASCs) both after 24 h (h) of CB treatment and 24 h after CB wash-out. CB influenced the metabolism, proliferation, and morphology of hASCs in a dose-dependent manner, in association with progressive disorganization of actin microfilaments. Furthermore, the removal of CB highlighted the ability of cells to restore their cytoskeletal organization. Finally, atomic force microscopy (AFM) revealed that cytoskeletal changes induced by CB modulated the viscoelastic properties of hASCs, influencing their stiffness and viscosity, thereby affecting adipogenic fate.
Cytochalasin B binding to Ehrlich ascites tumor cells and its relationship to glucose carrier
Biochim Biophys Acta 1981 Apr 6;642(2):392-404.PMID:7284364DOI:10.1016/0005-2736(81)90455-7.
Cultured Ehrlich ascites tumor cells equilibrate D-glucose via a carrier mechanism with a Km and V of 14 mM and 3 mu mol/s per ml cells, respectively. Cytochalasin B competitively inhibits this carrier-mediated glycose transport with an inhibition constant (Ki) of approx. 5.10(-7) M. Cytochalasin E does not inhibit this carrier function. With Cytochalasin B concentrations up to 1.10(-5) M, the range where the inhibition develops to practical completion, three discrete Cytochalasin B binding sites, namely L, M and H, are distinguished. The Cytochalasin B binding at L site shows a dissociation constant (Kd) of approx. 1.10(-6) M, represents about 30% of the total Cytochalasin B binding of the cell (8.10(6) molecules/cell), is sensitively displaced by cytochalasin E but not by D-glucose, and is located in cytosol. The Cytochalasin B binding to M site shows a Kd of 4--6.10(-7) M, represents approx. 60% of the total saturable binding (14.10(6) molecules/cell), is specifically displaced by D-glucose with a displacement constant of 15 mM, but not by L-glucose, and is insensitive to cytochalasin E. The sites are membrane-bound and extractable with Triton X-100 but not by EDTA in alkaline pH. The Cytochalasin B binding at H site shows a Kd of 2--6.10(-8) M, represents less than 10% of the total sites (2.10(6) molecules/cell), is not affected by either glucose or cytochalasin E and is of non-cytosol origin. It is concluded that the Cytochalasin B binding at M site is responsible for the glucose carrier inhibition by Cytochalasin B and the Ehrlich ascites cell is unique among other animal cells in its high content of this site. Approx. 16-fold purification of this site has been achieved.
Cytochalasin B induces cellular DNA fragmentation
FASEB J 1990 Sep;4(12):3021-7.PMID:2394319DOI:10.1096/fasebj.4.12.2394319.
Cellular DNA fragmentation can be induced in many biological instances without plasma membrane damage. The fungal metabolite, Cytochalasin B, is capable of modifying numerous cellular functions related to DNA synthesis. In this work it is demonstrated that Cytochalasin B is capable of inducing DNA fragmentation in a number of cells lines. This DNA fragmentation occurs before plasma membrane lysis and over a period of hours. Cytochalasin E and villin, agents that act on the microfilaments, also induce DNA fragmentation. Phorbol dibutyrate, a diacylglyceral analog, is able to inhibit cytochalasin B-induced DNA fragmentation in a dose-dependent fashion. These findings support the interpretation that Cytochalasin B is inducing DNA fragmentation via its effect on the actin filaments.
Mitochondrial aggregation caused by Cytochalasin B compromises the efficiency and safety of three-parent embryo
Mol Hum Reprod 2022 Oct 28;28(11):gaac036.PMID:36264122DOI:10.1093/molehr/gaac036.
It is widely accepted that Cytochalasin B (CB) is required in enucleation of the oocyte in order to stabilize the cytoplasm. However, CB treatment results in the uneven distribution of mitochondria, with aggregation towards the nucleus, which might compromise the efficiency and safety of a three-parent embryo. Here, we demonstrated that CB treatment affected mitochondrial dynamics, spindle morphology and mitochondrial DNA carryover in a concentration-dependent manner. Our results showed that mouse oocytes treated with over 1 μg/ml CB exhibited a more aggregated pattern of mitochondria and diminished filamentous actin expression. Abnormal fission of mitochondria together with changes in spindle morphology increased as CB concentration escalated. Based on the results of mouse experiments, we further revealed the practical value of these findings in human oocytes. Chip-based digital PCR and pyrosequencing revealed that the mitochondrial carryover in reconstituted human embryos was significantly reduced by modifying the concentration of CB from the standard 5 μg/ml to 1 μg/ml before spindle transfer and pronuclear transfer. In conclusion, our findings provide an optimal manipulation for improving the efficiency and safety of mitochondrial replacement therapy.
The real deal: using Cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells
Anticancer Res 2014 May;34(5):2195-202.PMID:24778021doi
Background/aim: Sonodynamic therapy (SDT) is a form of ultrasound therapy in which chemotherapeutic agents known as sonosensitizers are administered to increase the efficacy of ultrasound's preferential damage to neoplastic cells. Perhaps one of the most intriguing capabilities of ultrasound is its ability to preferentially lyse cells based on size. Cytochalasin B is a cytokinesis inhibitor that preferentially enlarges and multinucleates malignant cells, making them much more sensitive to ultrasonic irradiation. Materials and methods: The present study investigated the extent of preferential damage inflicted by Cytochalasin B on U937 leukemia/human blood cell populations. Cell mixtures were treated with Cytochalasin B and then sonicated under a relatively low intensity (3W/cm(2)). Results: Cytochalasin B preferentially damages U937 cells both before and after sonication. This agent also reduces rapid proliferation as the clonogenicity of U937 cells was considerably reduced following treatment. Conclusion: Cytochalasin B may have profound therapeutic applications when combined with SDT.